Application of xanthohumol compound in preparation of medicine for preventing and treating streptococcosis of aquatic animals
By using chlorhexidol compounds to inhibit β-hemolytic/cytolytic and biofilm synthesis of Streptococcus agalactia, the problem of antibiotic resistance in streptococci disease in aquatic animals was solved, and efficient and low-toxic prevention and treatment effects were achieved. Provides green and safe alternative medicines.
Patent Information
- Application Number
- CN202411039634.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-12
AI Technical Summary
The increased resistance of existing antibiotics and synthetic chemicals to Streptococcus alactissia has led to a decrease in the prevention and control effect of streptococcosis in aquatic animals, and the use brings environmental pollution and health risks.
Using oxalhumpol compounds, including oxalhumpol, isochlorhumpol and their derivatives, as drugs for prevention and control of streptococcosis in aquatic animals, by inhibiting β-hemolytic/cytolytic and biofilm synthesis of Streptococcus agalactiae, Reduce pathogenicity and drug resistance of pathogens.
Yellowkhumpol and isochhumpol significantly inhibit the β-hemolytic/cellular activity and biofilm synthesis of Streptococcus alactis, have high efficiency, low toxicity and low residue prevention and treatment effects, reduce the drug resistance probability of pathogens, and provide green Safe alternative medicine solutions.
Smart Images

Figure CN118924712A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to application of xanthohumol compounds in preparing drugs for preventing and treating streptococcal diseases in aquatic animals, belonging to the technical field of bacterial disease prevention and control in breeding animals. Background Art
[0002] Streptococcus agalactiae is one of the main pathogens of streptococcal disease in aquatic animals. Streptococcus agalactiae is a Gram-positive pathogen with a wide range of hosts. It is not only an important pathogen that causes human sepsis and neonatal meningitis, but also a pathogen that causes a variety of animal diseases such as cow mastitis and fish sepsis, which brings great harm to human health, animal husbandry and aquaculture. At present, antibiotics and synthetic chemical drugs are still the main drugs for preventing and treating bacterial diseases. However, the abuse or long-term use of such antibacterial drugs makes streptococci resistant to many drugs. Its resistance rate continues to rise, the resistance spectrum continues to expand, and the effect of medication continues to decline. Farmers have to increase the amount of drugs, which causes drug residues, environmental pollution, imbalance of the aquaculture microecological environment, and increased risk of drug resistance factors spreading to human and animal pathogens, which seriously threatens public health safety and public health. Therefore, the development of antibiotics against Streptococcus agalactiae and alternatives to synthetic chemical drugs has become an urgent and practical need. Natural drugs have the advantages of being green and safe, low in residue, low in toxicity, multifunctional and low in drug resistance. They are green and safe drugs advocated in recent years to solve the problem of pathogen resistance. The relevant natural product library has become an important tool for drug discovery, drug target identification and drug-related application exploration.
[0003] Streptococcus agalactiae is a conditional pathogen, and its pathogenicity mainly depends on a large number of virulence factors encoded by it, including colonization, invasion, biofilm formation and immune escape. Among them, β-hemolytic / cytolyticin and its biofilm formation are the key to the pathogenicity of Streptococcus agalactiae. β-hemolytic / cytolyticin is a pigment catalyzed and synthesized by a series of active proteins encoded and expressed by the cyl operon, which can dissolve the cell membrane, cause the disorder of cell membrane structure and function, and cause the host cytoplasmic substances to leak out, thus leading to the death of host cells. Biofilm is a microbial aggregate formed in large quantities by microorganisms through their own secretion of polysaccharide matrix, fibrin and lipoprotein and other sticky substances, attached to the contact surface of living or inanimate objects, and stimulated by the external environment. Biofilm is a natural barrier to defend against antimicrobial drugs, reducing the sensitivity of pathogens to antibiotics. Once a biofilm is formed, the resistance of pathogens to antimicrobial agents can be increased by 10 to 1000 times. It is reported that 65% of human bacterial infections and 80% of chronic infections are related to biofilm. Therefore, inhibiting the formation of biofilms or degrading existing biofilms is a very promising strategy to reduce bacterial resistance. It is also a way to fundamentally solve the problem of pathogen resistance caused by biofilms. Summary of the invention
[0004] The technical problem solved by the present invention is to provide compounds having a preventive and therapeutic effect on streptococcal diseases in aquatic animals, namely xanthohumol compounds.
[0005] The invention discloses an application of a xanthohumol compound in preparing a drug for preventing and treating streptococcal disease in aquatic animals. The xanthohumol compound is xanthohumol, isoxanthohumol, a xanthohumol derivative or an isoxanthohumol derivative.
[0006] In one embodiment of the present invention, the pathogen of streptococcal disease in aquatic animals is Streptococcus agalactiae.
[0007] In one embodiment of the present invention, the aquatic animal is tilapia.
[0008] In one embodiment of the present invention, the effective inhibitory concentration of xanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae is 6.25 μg / mL, while the effective inhibitory concentration on the biofilm synthesis of Streptococcus agalactiae is 50 μg / mL; the effective inhibitory concentration of isoxanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae is 25 μg / mL, while the effective inhibitory concentration on the biofilm synthesis of Streptococcus agalactiae is 50 μg / mL.
[0009] In an embodiment of the present invention, the effective therapeutic concentration of xanthohumol is 80-400 mg of xanthohumol per kilogram of feed mix.
[0010] In one embodiment of the present invention, the dosage form of the control drug is a mixed liquid, microemulsion, nanoemulsion, medicated bath liquid, capsule, oral capsule, paint, powder, granule, pellet, micropellet or different dosage forms of drugs prepared with pharmaceutically acceptable carriers and excipients.
[0011] Compared with the prior art, the present invention has the following beneficial effects:
[0012] 1. The xanthohumol, isoxanthohumol and their derivatives disclosed in the present invention are used for the preparation of drugs for preventing and treating streptococcal diseases in aquatic animals. In vitro experiments show that when the concentration of xanthohumol is 10 μg / mL, the inhibition rate of β-hemolytic / cytolytic activity of Streptococcus agalactiae is 100%, and the inhibition rate of xanthohumol on biofilm of Streptococcus agalactiae is 56.53%. When the concentration of isoxanthohumol is 10 μg / mL, the inhibition rate of β-hemolytic / cytolytic activity of Streptococcus agalactiae is 81%, and the inhibition rate of isoxanthohumol on biofilm of Streptococcus agalactiae is 59.30%. In vitro experiments have shown that both xanthohumol and isoxanthohumol have significant inhibitory effects on β-hemolytic / cytolytic activity and biofilm synthesis of Streptococcus agalactiae. LD 80The protection rate of artificially infected tilapia with Streptococcus agalactiae was 8.33% to 66.67%. The protection rate of feeding with 98% pure xanthohumol mixed feed was 41.67% to 79.17%, indicating that xanthohumol has a significant preventive effect on tilapia streptococcal disease.
[0013] 2. The natural compound xanthohumol or isoxanthohumol for preventing and treating streptococcal disease in aquatic animals disclosed in the present invention has the advantages of wide source, low probability of drug resistance, low residue, green and safe, small toxic and side effects, no pollution, high efficiency and low cost.
[0014] 3. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the natural compound xanthohumol for preventing and treating aquatic animal streptococcal disease disclosed in the present invention for Streptococcus agalactiae reach 50 μg / mL and 100 μg / mL respectively. The inhibition rate of β-hemolysis / cytolysis activity of Streptococcus agalactiae at 6.24 μg / mL (1 / 8 MIC) is 100%, and the inhibition rate of biofilm synthesis at 25.00 μg / mL (1 / 2 MIC) is 64.35%. Its inhibitory concentration for β-hemolysis / cytolysis activity and biofilm synthesis of Streptococcus agalactiae is significantly lower than MIC. Isoxanthohumol has a significant inhibition of β-hemolysis / cytolysis activity of Streptococcus agalactiae at low concentration (1 / 4 MIC), with an inhibition rate of 100%. It has a significant inhibition of biofilm synthesis activity at a concentration of (1 / 2 MIC), with an inhibition rate of 87.92%. Its minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for Streptococcus agalactiae reach 100μg / mL and 200μg / mL respectively, which are much higher than the β-hemolytic / cytolytic activity and biofilm synthesis activity against Streptococcus agalactiae. This means that under low-dose conditions, xanthohumol or isoxanthohumol can significantly reduce the pathogenicity of Streptococcus agalactiae without affecting the growth of Streptococcus agalactiae, achieving the effect of preventing and treating streptococcal disease, while significantly reducing the probability of drug resistance due to survival pressure, which can effectively solve the current problem of drug resistance of bacterial diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 This is a graph showing the inhibition rate of different concentrations of xanthohumol or isoxanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae in Example 1.
[0016] Figure 2 This is a diagram of biofilm synthesis at different culture times in Example 2.
[0017] Figure 3 This is a graph showing the inhibition rate of biofilm activity of Streptococcus agalactiae at different concentrations of xanthohumol or isoxanthohumol in Example 2.
[0018] Figure 4The effect of ten generations of passage on the β-hemolytic / cytolytic activity of xanthohumol-treated and untreated Streptococcus agalactiae in Example 4. In the figure, (A) is Streptococcus agalactiae treated with xanthohumol, and (B) is Streptococcus agalactiae not treated with xanthohumol.
[0019] Figure 5 This is the survival curve of tilapia infected with different concentrations of Streptococcus agalactiae in Example 6.
[0020] Figure 6 The survival curves of tilapia artificially infected with Streptococcus agalactiae were obtained by different doses of 20% crude extract of xanthohumol or 98% xanthohumol. A is 20% crude extract of xanthohumol, and B is 98% pure xanthohumol. *P<0.05, **P<0.01.
[0021] Figure 7 The tissue sections of pathological changes after using xanthohumol or not in Example 7, wherein Ai represents aggregation of inflammatory cells; Ws represents watery changes; Hm represents iron-containing heme; Di represents enlarged distance; Gt represents thickening and shortening of gill filaments; Ep represents basal hyperplasia; Mb represents rupture of muscle tissue; Mi represents dissolution of muscle fibers; Va represents vacuoles; and Nl represents dissolution of cell nuclei. DETAILED DESCRIPTION
[0022] The present invention finds that xanthohumol, isoxanthohumol and their derivatives can be used in the preparation of drugs for the prevention and treatment of streptococcal diseases in aquatic animals. Xanthohumol, isoxanthohumol and their derivatives can effectively inhibit the key virulence factors β-hemolysis / cytolysin and biofilm of Streptococcus agalactiae. Xanthohumol mixed with feed was fed to tilapia artificially infected with Streptococcus agalactiae, and it was found that xanthohumol can effectively treat tilapia streptococcal diseases.
[0023] In one embodiment of the present invention, the pathogen of streptococcal disease in aquatic animals is Streptococcus agalactiae PBSA0901.
[0024] The xanthohumol described in the present invention is a flavonoid compound isolated from the perennial climbing herbaceous plant hops (Humulus lupulus L.) of the Cannabaceae family (Cannabaceae), and isoxanthohumol is an isomer produced by xanthohumol during heating. During the boiling process of the wort for brewing beer, most of the xanthohumol is isomerized to isoxanthohumol. The content of isoxanthohumol in beer is much higher than that of xanthohumol, and isoxanthohumol also has the activity of inhibiting the toxicity of Streptococcus agalactiae. Xanthohumol and isoxanthohumol have anti-tumor, anti-angiogenesis and antioxidant effects. The present invention has found that xanthohumol and isoxanthohumol have significant inhibitory effects on the β-hemolysis / cytolysis activity and biofilm activity of Streptococcus agalactiae. Xanthohumol and isoxanthohumol greatly reduce the pathogenicity of Streptococcus agalactiae without affecting the growth of Streptococcus agalactiae, so that the bacteria either become the symbiotic flora of the host or are easily recognized and removed by the host immune system. Because it has no effect on the growth of Streptococcus agalactiae, it greatly reduces the probability of the bacteria developing drug resistance due to survival pressure. It can effectively solve the current problem of pathogen resistance and has broad application prospects in preventing and controlling bacterial diseases in aquatic animals.
[0025] In an embodiment of the present invention, the aquatic animal is tilapia.
[0026] In an embodiment of the present invention, the effective therapeutic concentration of xanthohumol is 80-400 mg of xanthohumol per kilogram of feed mix.
[0027] The dosage form of xanthohumol can be a commonly used dosage form in the art, and can be a different dosage form of medicine prepared together with a pharmaceutically acceptable carrier or excipient, such as a mixing liquid, a microemulsion, a nanoemulsion, a microcapsule, a micropellet, a powder, and a dust, etc. In a specific embodiment of the present invention, the mixing liquid is prepared by dissolving xanthohumol in an anhydrous ethanol solution, adjusting it to a desired concentration, and spraying it on the basal diet to prepare the mixing liquid.
[0028] In one embodiment of the present invention, the effective inhibitory concentration of xanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae is 6.25 μg / mL, while the effective inhibitory concentration on the biofilm synthesis of Streptococcus agalactiae is 50 μg / mL; the effective inhibitory concentration of isoxanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae is 25 μg / mL, while the effective inhibitory concentration on the biofilm synthesis of Streptococcus agalactiae is 50 μg / mL.
[0029] In an embodiment of the present invention, the xanthohumol is a 20% xanthohumol crude extract or a 98% pure xanthohumol compound. The recommended effective therapeutic concentration of xanthohumol is 900 mg / kg for a 20% xanthohumol crude extract and 400 mg / kg for a 98% pure xanthohumol compound.
[0030] The specific embodiments of the present invention are further described below in conjunction with the examples, but the present invention is not limited to the scope of the examples. The Streptococcus agalactiae PBSA0901 used in the examples was isolated from infected tilapia (O. niloticus) collected from the Dazhipo tilapia farm in Wenchang City, Hainan Province, China.
[0031] Example 1 Inhibitory activity of xanthohumol or isoxanthohumol on β-hemolysis / cytolysin of Streptococcus agalactiae
[0032] 1. Preparation of Streptococcus agalactiae Suspension
[0033] The PBSA0901 strain of Streptococcus agalactiae stored at -80°C was thawed at room temperature, inoculated with 1% of the inoculum into new brain heart infusion (BHI) liquid medium, cultured at 37°C with shaking for 12 h, washed three times with 0.01 mmol / L PBS (pH 7.2) at 3000 r / min, centrifuged for 5 min, and resuspended in 0.01 mmol / L PBS (pH 7.2) until the bacterial suspension reached an OD of 620nm The concentration of 0.8 was used to prepare the test bacterial suspension and kept at 4°C for later use.
[0034] 2. Treatment of Streptococcus agalactiae with xanthohumol or isoxanthohumol
[0035] According to the inoculation volume of 5%, OD 620nm The test bacterial suspension with a concentration of 0.8 was inoculated into fresh BHI medium containing 0 μg / mL (blank group) and 10 μg / mL xanthohumol / isoxanthohumol (experimental group), cultured with shaking for 6 h, centrifuged at 3000 r / min for 5 min, and the cells were collected and resuspended in 0.01 mmol / L PBS (pH 7.2) and diluted to OD 620nm is 0.8 to prepare the test bacterial suspension.
[0036] 3. Preparation of Red Blood Cell Suspension
[0037] Take an appropriate amount of sterile sheep blood in a centrifuge tube, centrifuge at 3000r / min for 5min, remove the supernatant, add 0.01mmol / LPBS (pH7.2) (0.2% G-PBS) containing 0.2% glucose to wash 3 times (until the supernatant is no longer red), mix the washed red blood cell suspension with 0.2% G-PBS, and prepare OD 575nm A red blood cell suspension of 2.
[0038] 4. Detection of β-hemolytic / cytolytic activity of Streptococcus agalactiae
[0039] The β-hemolytic / cytolytic activity of Streptococcus agalactiae was detected by the two-fold gradient dilution method, that is, 300 μL of the test bacterial suspension was aspirated into the first column of the sterile 96-well plate, and the suspension was diluted twice with 0.01 mmol / L PBS (pH 7.2) solution. 150 μL of red blood cell suspension was added to each well, placed in a 37°C constant temperature and humidity incubator, and incubated for 1 hour. After the incubation solution was mixed, it was transferred to a 1.5 mL centrifuge tube, centrifuged at 4°C 3000 r / min for 10 minutes, and 200 μL of the supernatant was taken to a new 96-well plate. The absorbance value at 540 nm was detected by an ELISA instrument. Each 96-well plate was set with a positive control and a negative control. The positive control well used 0.1% SDS solution instead of the bacterial suspension, and the negative control used 0.01 mmol / L, pH 7.2 PBS instead of the bacterial suspension. Each sample was measured in parallel 6 times, and the hemolysis rate (HR) was calculated according to formula (a)
[0040]
[0041] In formula (a), A i , A0′ and A0 are the average absorbance values of sample wells, negative control wells and positive control wells at 540 nm, respectively.
[0042] With bacterial concentration as the horizontal axis and HR as the vertical axis, a scatter plot was drawn using OriginPro8.5.1SR2 (OriginLab Corporation, USA), and the scatter plot was fitted with equation (formula (b)) to obtain the fitting equation. The concentration of the bacterial suspension with a half-hemolysis rate (HR) was calculated based on the fitting equation. 50 ), and calculate the hemolysis titer (HT) according to formula (c).
[0043] y=B2+(B1-B2) / (1+(x / x0) p ) (b)
[0044] where y is HR, x is the bacterial suspension concentration, B1, B2, x0 and p are experimentally obtainable constants.
[0045] HT=10 9 / HR 50 (c)
[0046] IR i =(1-HT i / HT0)×100% (d)
[0047] IR i is the inhibition rate of the i-th candidate natural compound, HT i is the hemolytic titer of Streptococcus agalactiae treated with the ith candidate natural compound, and HT0 is the hemolytic titer of the blank test bacterial suspension.
[0048] 5. Effect of xanthohumol or isoxanthohumol concentration on hemolysis inhibition rate
[0049] According to the method in 4, the β-hemolytic / cytolytic activity of Streptococcus agalactiae PBSA0901 treated with 0, 0.39, 0.78, 1.56, 3.13 and 6.25 μg / mL xanthohumol and 0, 1.56, 3.125, 6.25, 12.5, 25 μg / mL isoxanthohumol was determined, and the detection was carried out 6 times in parallel. The inhibition rate of xanthohumol / isoxanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae PBSA0901 was calculated. According to the method in 4, Origin Pro 8.5.1 SR2 (Origin Lab Corporation, USA) was used to draw a scatter plot, and the scatter plot was fitted with equation (b) to obtain the fitting equation. The half-hemolytic rate bacterial suspension concentration (EC) was calculated according to the fitting equation. 50 ), the detection results of β-hemolytic / cytolytic activity of Streptococcus agalactiae showed that the inhibition rate of 10 μg / mL xanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae PBSA0901 was 100%, and the inhibition rate of isoxanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae PBSA0901 was 81%.
[0050] The results of the effects of 0, 0.39, 0.78, 1.56, 3.13 and 6.25 μg / mL xanthohumol on the inhibition rate of β-hemolytic / cytolytic activity of Streptococcus agalactiae PBSA0901 showed that: Figure 1 As shown, when the concentration of xanthohumol is 6.25 μg / mL, the inhibition rate of xanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae has reached 100%. The fitting result is y=1.053-0.827 / (1+(x / 2.929) 2.492 ), correlation coefficient (R 2 ) is 0.968. EC is calculated according to the fitting formula 50 The results of the effect of isoxanthohumol on the hemolysis inhibition rate using 0, 1.56, 3.13, 6.25, 12.5, and 25 μg / mL concentrations showed that (eg Figure 1 ), when the concentration of isoxanthohumol is 25 μg / mL, the inhibition rate of isoxanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae reaches 100%. The fitting result is y=2.191-1.946 / (1+(x / 34.5455 1.405 ). 2 The EC was calculated based on the fitting formula. 50 It is 9.039±0.273μg / mL.
[0051] Example 2 Inhibitory activity of xanthohumol or isoxanthohumol on biofilm synthesis of Streptococcus agalactiae
[0052] 1. Effect of culture time on biofilm formation of Streptococcus agalactiae
[0053] The amount of biofilm generated was detected by crystal violet staining. The test bacterial solution was prepared according to the method of Example 1 and diluted with PBS (0.01 mmol / L, pH 7.2) to OD 620nm is 0.2. In the experimental group, 100 μL of the bacterial suspension was added to each well of a 96-well plate, and 100 μL of fresh brain heart infusion broth (BHI) was added. In the control group, 100 μL of BHI and 100 μL of PBS were added. Six parallels were set up for each group, and the 96-well plate was placed in a 37°C incubator for incubation for 0, 4, 6, 12, 18, 24, 30, 36, 42 and 48 h. The crystal violet staining method was used to determine the amount of biofilm formation of Streptococcus agalactiae: wash with 0.01 mmol / L PBS (pH7.2) three times, dry naturally, add 200 μL of 0.1% crystal violet for staining for 15 minutes, wash with 0.01 mmol / L PBS (pH7.2) three times, dry naturally, add 200 μL of 33% acetic acid, let stand at room temperature for 30 minutes, and use an enzyme reader to detect the absorbance at a wavelength of 570 nm. The OD value is the OD of the control group. 570nm The sum of the six replicate means and the standard deviation of the six replicates of the control group. Biofilm assay standard: OD 570 ≤OD, if no biofilm is produced, it is negative (-); OD if weak biofilm is produced (±) 570 ≤2OD and OD producing moderate biofilm 570 ≤4OD<2OD is positive (+), the OD that produces strong biofilm 570 >4 OD was strongly positive (++) Each S. agalactiae PBSA0901 sample was tested in six parallel wells.
[0054] The results showed that the OD of the experimental group 570nm The values were significantly higher than those in the control group. Figure 2 As shown, Streptococcus agalactiae PBSA0901 was incubated at 37°C for 24, 42 and 48 hours, and the OD 570nm >4OD), respectively, produced strong biofilm, i.e., strongly positive (++). At 18 hours and 36 hours, 2OD <OD 570 ≤4OD, and moderate biofilm, i.e. positive (+). At 4, 6, 12, and 30 hours, OD <OD 570 ≤2OD produced weak biofilm, i.e., weak positive (±). Since strong biofilm was generated at 24, 42, and 48 h in this study, these three time points could be selected for biofilm inhibition experiments, and 24 h was selected as the incubation time for biofilm.
[0055] 2. Effects of xanthohumol or isoxanthohumol on biofilm of Streptococcus agalactiae
[0056] The test bacterial solution was diluted with 0.01mmol / L PBS (pH7.2) to OD 620nm The experimental group was added with 100 μL of 10 μg / mL xanthohumol / isoxanthohumol, and the control group was added with 100 μL of 0 μg / mL xanthohumol / isoxanthohumol. The bacterial suspension was added to the 96-well plates of the experimental group and the control group at 100 μL per well. The negative controls were 100 μL BHI liquid culture medium and 100 μL PBS, respectively. Six parallel wells were set up in each group, and the 96-well plates were placed in a 37°C incubator for 24 hours. The crystal violet staining method was used to determine the inhibitory activity of xanthohumol / isoxanthohumol on the biofilm formation of Streptococcus agalactiae. The results showed that the inhibition rate of 10 μg / mL xanthohumol on the biofilm formation of Streptococcus agalactiae was 56.53%, while the inhibition rate of 10 μg / mL isoxanthohumol on the biofilm formation of Streptococcus agalactiae was 59.30%.
[0057] 3. Effects of different concentrations of xanthohumol or isoxanthohumol on biofilm formation of Streptococcus agalactiae
[0058] OD 620nm The test bacterial solution with a concentration of 0.2 was added to a 96-well plate at a rate of 100 μL per well, and 100 μL of xanthohumol or isoxanthohumol of the same concentration gradient at concentrations of 50, 25, 12.5, 6.25, and 3.13 μg / mL was added. In this experiment, the control group was set as 0 μg / mL xanthohumol / isoxanthohumol 100 μL as the positive control. The negative control group was added with 100 μL BHI and 100 μL PBS. Each group had 6 parallel wells, and the 96-well plate was placed in a 37°C incubator for 24 hours. The crystal violet staining method was used to determine the inhibitory activity of xanthohumol / isoxanthohumol on the biofilm formation of Streptococcus agalactiae at different concentrations. The half inhibition rate concentration (EC 50 ).
[0059] The results are as follows Figure 3 When the concentration was 50 μg / mL, the inhibition rates of xanthohumol and isoxanthohumol on biofilm formation of Streptococcus agalactiae reached 87.27% and 88%, respectively. The fitting equations of the scatter plots of xanthohumol and isoxanthohumol concentrations VS the inhibition rate of biofilm formation of Streptococcus agalactiae were y=8.88-9.219 / (1+(x / 5.95×10 4 ) 0.267 ) and y = 0.975-0.578 / (1+(x / 16.887) 1.528 ), their R 2 The EC values of xanthohumol and isoxanthohumol calculated according to the fitting equation were 0.916 and 0.999, respectively. 50They were 14.901±0.668μg / mL and 16.887±0.340μg / mL respectively.
[0060] Example 3 Determination of MIC and MBC of xanthohumol or isoxanthohumol against Streptococcus agalactiae by test tube method
[0061] The MIC of the test bacteria was determined by the broth test tube method in the Microbiological Clinical Laboratory Standards and Operation Specifications (M07-A9) formulated by the National Committee for Clinical Laboratory Standards (NCCLS). PBS (0.01mmol / L, pH 7.2) was used to prepare a 1600μg / mL culture medium of xanthohumol or isoxanthohumol, and the concentration of xanthohumol or isoxanthohumol was diluted to 3, 6, 13, 25, 50, 100, 200, 400, 800, 1600μg / mL by a 2-fold dilution method. In addition, a culture medium without xanthohumol or isoxanthohumol was set as a control, and 6 parallels were set for each concentration. 9mL test tubes were used, and 5mL of the above-mentioned concentration of xanthohumol or isoxanthohumol culture medium was added to each tube, and 10% of the OD was inoculated. 620nm A suspension of Streptococcus agalactiae with a pH of 0.8 was cultured at 37°C for 24 hours. The test tube was taken out and slightly shaken. The turbidity of the culture in the test tube was observed with the naked eye. The maximum concentration at which turbidity was invisible to the naked eye was recorded as the MIC of xanthohumol or isoxanthohumol.
[0062] Based on the MIC, 20 μL of sample solution was drawn from each well and evenly coated on BHI solid medium. After culturing at 37°C for 24 hours, the concentration on the solid medium was ranked from low to high with the concentration at which no bacteria were found on the first solid medium as the MBC. The results showed that the MIC of xanthohumol against the test strain of Streptococcus agalactiae was 50 μg / mL and the MBC was 100 μg / mL. The MIC of isoxanthohumol against the test strain of Streptococcus agalactiae was 100 μg / mL and the MBC was 200 μg / mL.
[0063] Example 4 Effect of Subculturing on the β-Hemolytic / Cytolytic Activity of Streptococcus agalactiae PBSA0901 Treated with Xanthohumol
[0064] According to the inoculum volume of 1%, OD 620nm 0.8 μg / mL suspension of Streptococcus agalactiae PBSA0901 was inoculated into brain heart infusion medium containing 0 μg / mL xanthohumol (blank control) and 6.25 μg / mL xanthohumol (experimental group), with 3 parallel experiments in each group. The culture was shaken for 6 h and the OD was measured. 620nm When the absorbance value was 0.8, the bacterial suspension was streaked on the blood plate to observe the hemolysis zone of the colony. The blank control and experimental group bacterial suspensions were continuously propagated in brain heart infusion medium for 10 generations. After each generation, the bacterial suspension was smeared on the blood plate to observe the hemolysis. The results are shown in Table 1 and Figure 4 .
[0065] like Figure 4 As shown: after ten consecutive generations of xanthohumol treatment, there was no hemolytic zone, while there was a hemolytic zone in the control group. The results showed that the β-hemolytic / cytolytic activity of Streptococcus agalactiae treated with xanthohumol could not be restored by subculture.
[0066] Table 1 Effect of subculture on the β-hemolytic / cytolytic activity of Streptococcus agalactiae PBSA0901 treated with xanthohumol
[0067] Generation Algebra Control group Experimental Group 1 + - 2 + - 3 + - 4 + - 5 + - 6 + - 7 + - 8 + - 9 + - 10 + -
[0068] Note: + indicates that the BHI defibrinated sheep blood agar plate has a hemolytic zone; - indicates that the BHI defibrinated sheep blood agar plate has no hemolytic zone.
[0069] Example 5 Acute toxicity test of xanthohumol on tilapia
[0070] 1. Preparation of Drug Solution
[0071] Weigh an appropriate amount of xanthohumol into a 50 mL centrifuge tube, add 1 mL of pure DMSO to dissolve it, and dilute it with PBS buffer to a xanthohumol solution with a final concentration of 300, 150, and 75 mg / mL.
[0072] 2. Tilapia gavage
[0073] A total of 120 healthy tilapias, with a body length of (10±2) cm and a body weight of (25±5) g, which had been temporarily reared for 14 days, were randomly allocated to eight 125L aquariums (0.5m×0.5m×0.5m), with 15 fish in each tank. The eight tanks were divided into three experimental groups and one control group, with two parallel tanks in each group. The fish were fed with basic feed for 7 days to adapt to the density environment. The rearing conditions were water temperature of 32±2℃, pH 7±0.5, dissolved oxygen (DO) higher than 7.4mg / L, and water was changed every 2 days with 1 / 4 of the water changed each time to keep the water environment continuously stable. After the adaptive feeding, the tilapia were fasted for 24 hours and gavaged with 0.2mL / 25g xanthohumol solution. After 4 hours, the equal volume was gavaged again. The total gavage dose was 750, 1500 and 3000mg / kg, respectively. After that, the original feeding conditions were still followed and the symptoms were observed for 14 days. Dead tilapia were promptly removed and routine disease tests were performed on the dead tilapia. The results showed that after 14 days of continuous observation, no death occurred in the tilapia in the experimental group and the control group. The swimming and reaction were normal, there was no abnormality in eating, and the water did not show obvious rapid turbidity. After the observation period, all tilapia were removed and the body surface was observed. There were no blood spots, ulceration, dephosphorization and other phenomena. The eyes were not turbid or congested. All tilapia were dissected. There was no fluid in the abdominal cavity, the organs were bright in color, there was no ulceration or swelling, and there was no water in the stomach and intestinal cavity. The liver, spleen, head kidney and brain were homogenized and mixed, spread on an agar plate, and cultured upside down at 37°C for 12 hours. Aseptic growth was observed.
[0074] Example 6 Protection rate of 20% crude xanthohumol extract or 98% pure xanthohumol against tilapia infected with Streptococcus agalactiae
[0075] 1. Preparation of bacterial suspension: Prepare bacterial suspension by the method of Streptococcus agalactiae in Reference Example 1.
[0076] 2. Establishment of a disease model of tilapia infected with Streptococcus agalactiae
[0077] 150 healthy tilapias, 10±2 cm in length and 25±5 g in weight, were randomly assigned to 10 125L aquariums (0.5 m×0.5 m×0.5 m) after temporary rearing for 14 days. Each aquarium contained 15 fishes. The aquariums were divided into 4 experimental groups and 1 negative control group. Each group contained two parallel glass tanks. The basic feed was raised for 7 days to adapt to the density environment. The rearing conditions were as in Example 5. After the adaptive rearing, the 4 experimental groups were respectively injected with a suspension of Streptococcus agalactiae to cause infection. The negative control group was injected with 0.01 mmol / L PBS (pH 7.2) buffer. The injection dose of tilapia in each group was shown in Table 2. The fishes were reared for another 14 days. The behavior of the experimental fishes was noted, their health status was recorded, and the number of dead fishes in the experiment was also recorded.
[0078] Table 2 Establishment of the disease model of tilapia with Streptococcus agalactiae
[0079] Group Bacterial concentration Challenge dose feed Negative control group 0CFU / mL 0.01mmol / LPBS (pH7.2) Basic feed Test Group 1 <![CDATA[7.5×10 5 CFU / mL]]> <![CDATA[3.0×10 6 CFU / kg]]> Basic feed Test Group 2 <![CDATA[7.5×10 6 CFU / mL]]> <![CDATA[3.0×10 7 CFU / kg]]> Basic feed Experiment 3 groups <![CDATA[7.5×10 7 CFU / mL]]> <![CDATA[3.0×10 8 CFU / kg]]> Basic feed Test 4 groups <![CDATA[7.5×10 8 CFU / mL]]> <![CDATA[3.0×10 9 CFU / kg]]> Basic feed
[0080] Note: OD of Streptococcus agalactiae 620nm =0.8, that is, 7.5×10 8 CFU / mL; injection volume 0.1mL / 25g.
[0081] After 14 days of continuous observation, the diseased tilapia showed symptoms such as protruding eyeballs, cloudy and white eyes or both eyes, and swollen abdominal cavity. After the death of the diseased fish, it was promptly dissected and the liver and spleen were observed to be enlarged, and the gastrointestinal tract was filled with water or yellow mucus, and the mucus and water would also diffuse into the abdominal cavity. The dead tilapia was re-isolated and identified as the pathogen, and the infected pathogen was identified as Streptococcus agalactiae.
[0082] The cumulative mortality curves of tilapia in each group are as follows Figure 5 As shown, the scatter plot fitting equation of challenge dose VS mortality is y = 1.895 × Lg (x) -2.985 (R 2 =0.9591). The LD of tilapia was calculated by Eq. 80 3.0×10 8 CFU / kg. Pathogen identification results The strains isolated and purified from tilapia were all Streptococcus agalactiae after 16S-rDNA detection.
[0083] 3. Protection rate of xanthohumol against tilapia artificially infected with Streptococcus agalactiae
[0084] 150 healthy tilapias with a body length of (10±2) cm and a body weight of (25±5) g were selected and randomly distributed to 10 125L aquariums (0.5m×0.5m×0.5m), with 15 fish in each tank. Three drug-treated groups, one model group and one blank group were set up, with two parallel glass tanks in each group. The basic feed was fed for 7 days to adapt to the density environment. The feeding conditions were water temperature of 32±2℃, pH 7±0.5, dissolved oxygen (DO) higher than 7.4mg / L, and water was changed every 2 days, with 1 / 4 of the water changed each time to keep the water environment stable. After the adaptive feeding, the fish were fasted for 24h and LD 80 =3.0×10 8 CFU / kg was injected intraperitoneally into tilapia, and feed was fed 2h after injection (injection dose and feed xanthohumol concentration are shown in Tables 3 and 4, where Table 3 shows the treatment effect of 20% xanthohumol crude extract on tilapia agalactiae disease, and Table 4 shows the treatment effect of 98% pure xanthohumol on tilapia agalactiae disease). The other conditions remained unchanged, and symptoms were observed for 14 days. Dead tilapia were removed in time. The remaining feed was removed 1h after each feeding to effectively maintain the stability of the aquaculture water environment.
[0085] Table 3 Experimental scheme for the therapeutic effect of 20% xanthohumol crude extract on tilapia Streptococcus agalactiae disease
[0086] Group Challenge dose Dosage of 20% xanthohumol crude extract Uninfected group 0.01mmol / LPBS (pH7.2) 0g / kg Infection group <![CDATA[3.0×10 8 CFU / kg]]> 0g / kg Low concentration dose <![CDATA[3.0×10 8 CFU / kg]]> 400mg / kg Medium concentration dose <![CDATA[3.0×10 8 CFU / kg]]> 800mg / kg High concentration dose <![CDATA[3.0×10 8 CFU / kg]]> 900mg / kg
[0087] Table 4 Experimental scheme for the therapeutic effect of 98% pure xanthohumol on tilapia Streptococcus agalactiae
[0088] Group Challenge dose 98% pure xanthohumol dosage Uninfected group 0.01mmol / LPBS (pH7.2) 0g / kg Infection group <![CDATA[3.0×10 8 CFU / kg]]> 0g / kg Low concentration dose <![CDATA[3.0×10 8 CFU / kg]]> 100mg / kg Medium concentration dose <![CDATA[3.0×10 8 CFU / kg]]> 200mg / kg High concentration dose <![CDATA[3.0×10 8 CFU / kg]]> 400mg / kg
[0089] The experimental results are shown in Tables 5 and 6. Table 5 shows the statistics of tilapia infected with Streptococcus agalactiae when mixed with 20% xanthohumol crude extract, and Table 6 shows the statistics of tilapia infected with Streptococcus agalactiae when mixed with 98% pure xanthohumol. Figure 6 .
[0090] Table 5 Statistics of Tilapia Infected with Streptococcus agalactiae by Mixing 20% Xanthohumol Extract and Feeding
[0091] Xanthohumol concentration Death amount (number) Relative protection rate (%) Blank group 0mg / kg 0 - Control group 0mg / kg 24 - 400mg / kg 22 8.33 800mg / kg 16 33.33 900mg / kg 8 66.67
[0092] Table 6 Statistics of Tilapia Infected with Streptococcus agalactiae by Feeding with 98% Pure Xanthohumol Mixture
[0093] Xanthohumol concentration Death amount (number) Relative protection rate (%) Blank group 0mg / kg 0 - Control group 0mg / kg 24 - 100mg / kg 14 41.67 200mg / kg 7 70.83 400mg / kg 5 79.17
[0094] Example 7 Histopathological examination
[0095] Tilapias that were temporarily reared for 14 days were randomly assigned to 125-L circulating glass aquariums. The aquariums were divided into four groups: uninfected and unmedicated group (C), infected and unmedicated group (F), uninfected and medicated group (G), and infected and medicated group (H). Each group had two parallel aquariums. All fish were fed twice a day at 10:00 and 17:00 at a feeding amount of 5% of the fish body weight. Tilapias in the uninfected and unmedicated groups and the uninfected and medicated groups were intraperitoneally injected with 200 μL of sterile PBS. Tilapias in the infected and unmedicated groups and the infected and medicated groups were intraperitoneally injected with LD 80 dose of Streptococcus agalactiae PBSA0901 suspension. The uninfected and infected groups were fed with a feed containing 400 mg / kg xanthohumol (purity 98%). Tilapia in the uninfected and infected groups were fed with a basal diet. Tilapia samples were taken on the 3rd day after intraperitoneal injection of the virus, 3 fish were taken from each tank, and then brain (Br), liver (Li), spleen (Sp), gill (Gi) and muscle (Mu) samples were taken, fixed with 4% paraformaldehyde fixative solution, dehydrated, transparent, embedded in paraffin, sliced 4-5 μm, stained with hematoxylin and eosin (H&E), sealed with Canada gum, and examined under a conventional optical microscope.
[0096] The results are as follows Figure 7 The experimental results showed that the tissues of the uninfected and unmedicated group (C) and the uninfected and medicated group (G) did not show abnormalities, while the brain tissues of the infected and unmedicated group (F) showed invasion and aggregation of inflammatory cells, thickening of the meninges and severe watery changes ( Figure 7 F-Br); the spleen has a lot of bleeding, the intercellular space becomes larger, and the iron-containing hemoglobin ( Figure 7 F-Sp; irregular arrangement of gill filaments, shortening and loss of tension, severe cases of gill filament dissolution, basal hyperplasia and gill fragment lysis ( Figure 7 F-Gi); muscle fibers are broken, arranged in disorder, with large gaps, and most muscle fibers are dissolved ( Figure 7 F-Mu); hepatocytes are swollen and hypertrophic, with unclear edges, small vacuoles appear in the form of honeycombs, which may develop into large vacuoles in severe cases, and nuclear condensation and lysis occur ( Figure 7 F-Li), and the infection medication group (H) fed with 400 mg / kg xanthohumol (purity 98%) in each tissue can effectively alleviate the histopathological changes in the brain, liver, spleen, gills, and muscles of tilapia, including accumulation of inflammatory cells, congestion, vacuoles, increased heme iron levels, thickening and shortening of gill filaments, and loosening of myofibrils. This shows that feeding 400 mg / kg xanthohumol (purity 98%) mixed with feed can effectively alleviate the symptoms of tilapia infected with Streptococcus agalactiae. In general, xanthohumol is a potential therapeutic compound for the prevention and treatment of streptococcal disease in tilapia.
Claims
1. Use of a xanthohumol compound in the preparation of a drug for preventing and treating streptococcal disease in aquatic animals, wherein the xanthohumol compound is xanthohumol, isoxanthohumol, a xanthohumol derivative or an isoxanthohumol derivative.
2. The use of the xanthohumol compound according to claim 1 in the preparation of a drug for the prevention and treatment of streptococcal disease in aquatic animals, characterized in that: The pathogen of the aquatic animal streptococcal disease is Streptococcus agalactiae.
3. The use of the xanthohumol compound according to claim 1 in the preparation of a drug for the prevention and treatment of streptococcal disease in aquatic animals, characterized in that: The aquatic animal is tilapia.
4. The use of the xanthohumol compound according to claim 1 in the preparation of a drug for the prevention and treatment of streptococcal disease in aquatic animals, characterized in that: The effective inhibitory concentration of xanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae is 6.25 μg / mL, while the effective inhibitory concentration on the biofilm synthesis of Streptococcus agalactiae is 50 μg / mL; the effective inhibitory concentration of isoxanthohumol on the β-hemolytic / cytolytic activity of Streptococcus agalactiae is 25 μg / mL, while the effective inhibitory concentration on the biofilm synthesis of Streptococcus agalactiae is 50 μg / mL.
5. The use of the xanthohumol compound according to claim 1 in the preparation of a drug for the prevention and treatment of streptococcal disease in aquatic animals, characterized in that: The effective therapeutic concentration of xanthohumol is 80-400 mg per kilogram of feed mixed with xanthohumol.
6. The use of the xanthohumol compound according to claim 1 in the preparation of a drug for the prevention and treatment of streptococcal disease in aquatic animals, characterized in that: The dosage form of the preventive and therapeutic drugs is mixed liquid, microemulsion, nanoemulsion, medicated bath liquid, capsule, oral capsule, coating, powder, granule, pellet, micropellet or different dosage forms of drugs prepared with pharmaceutically acceptable carriers and excipients.
